Cryo-Cell International, Inc. - 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended May 31, 2007, and the six-month period ended May 31, 2007. Cryo-Cell International, Inc. is engaged in the cellular processing and cryogenic storage of umbilical cord blood stem cells (U-Cord) for family use. The company also holds a 38% equity interest in Saneron CCEL Therapeutics, Inc. and is developing new services involving maternal placental stem cells (MPSC).
Key Financial Metrics
| Metric | Six Months Ended May 31, 2007 | Six Months Ended May 31, 2006 |
|---|---|---|
| Revenue | $8,623,037 | $8,171,537 |
| Net Loss | $(2,190,154) | $(804,605) |
| Loss Per Share (Basic & Diluted) | $(0.19) | $(0.07) |
| Operating Cash Flow | $(2,333,395) | $649,045 |
| Cash and Cash Equivalents (End of Period) | $4,607,731 | $7,742,975 |
| Total Assets | $12,985,803 | $14,640,383 |
| Total Liabilities | $17,065,801 | $16,732,529 |
| Stockholders' Deficit | $(4,079,998) | $(2,092,146) |
Margin Analysis: Cost of sales was 36% of revenue for the six months ended May 31, 2007, compared to 35% in the prior year. Marketing, general, and administrative expenses increased to 84% of revenue (up from 72% in the prior year).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 6% year-over-year, driven by a 17% increase in storage fees and price increases for new clients, partially offset by a 7% decrease in specimens processed.
- Expense Increases: Net loss widened significantly (172% increase) due to a 23% rise in marketing and administrative expenses and a 125% increase in research and development (R&D) expenses.
- Cash Flow Deterioration: Operating cash flow swung from positive ($649k) to negative ($2.3M). This was primarily due to the implementation of in-house financing plans for clients, increased R&D spending, and payments for prior year accounts payable.
- Accounting Changes: The company adopted SFAS 123R (Share-Based Payment) effective December 1, 2006, resulting in $122,702 of stock option compensation expense for the six-month period.
Outlook, Risks, and Management Commentary
- New Product Development: The company announced the isolation of maternal placental stem cells (MPSC) and plans to commercialize this service bundled with existing offerings. However, plans to launch fetal placental stem cell services (Plureon) were indefinitely postponed in April 2007 due to technological commercialization considerations.
- Liquidity: Management anticipates that current cash, marketable securities ($1.06M), and operating cash flows will be sufficient to fund operations for at least the next 12 months. The company has no indebtedness or lines of credit.
- Legal Proceedings: A significant patent infringement lawsuit by PharmaStem Therapeutics, Inc. was resolved favorably for Cryo-Cell. On July 9, 2007, the U.S. Court of Appeals for the Federal Circuit upheld a judgment in favor of Cryo-Cell, ruling the PharmaStem patents invalid on the grounds of obviousness. While PharmaStem may seek rehearing or Supreme Court review, the immediate threat of injunctions or damages has been removed.
- Risk Factors: Key risks include the uncertainty of commercializing new stem cell services (MPSC), potential government regulation of stem cell storage, and the impact of a proxy contest initiated by a dissident shareholder group (which incurred $160k in professional fees).
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the current cash position given the shift to negative operating cash flow and the $2.8M decrease in cash during the first half of the fiscal year.
- MPSC Commercialization: Assess the timeline and capital requirements for the launch of the new Maternal Placental Stem Cell service, as this is a key growth driver.
- Revenue Sharing Agreements (RSAs): Review the long-term liability of $3.75M related to RSAs, which requires perpetual revenue sharing on storage fees from specific geographic areas (NY, TX, FL, IL).
- Legal Finality: Confirm the status of the PharmaStem appeal to ensure no further litigation risks materialize regarding the invalidated patents.
- Stock-Based Compensation: Monitor the impact of the $406,000 in unrecognized compensation cost related to non-vested stock options over the next 1.8 years.